Award notice Supplies
Immunoglobuline humaine normale pour administration intraveineuse
Notice published in French. The AI analysis summarises it for you in your language.
- Public buyer
- Cliniques universitaires Saint Luc
Woluwe-Saint-Lambert - Place of performance
- 1200 Woluwe-Saint-Lambert, Brussels-Capital
not published: buyer's address - Amount awarded
- €16,277,080 excl. VAT
- Planned end of contract
- 7 October 2030
likely re-tender around April 2030 - Bids received
- 2
- Form
- Framework agreement
Multi-year contract: the buyer places orders as needs arise. - Procedure
- Open procedure
Any company may submit a bid. - Publication
- 22 October 2026
- Notice language
- French
AI analysis: go for it or not?
Summary in English, criteria, documents to provide and a GO / NO GO verdict in one minute.
Unlimited analyses during the 14-day Pro trial, no card needed.
Description
Le marché concerne la fourniture d’immunoglobuline humaine normale pour administration intraveineuse à une concentration de 10%.
Awarded to
CPV codes
European codes that classify what the contract is about. They are how we find the tenders for your trade.
33651520
Winning prices for comparable contracts
- A quarter below
- €290,000
- Median
- €403,000
- A quarter above
- €1,351,075
Amounts awarded (excl. VAT) over the last 3 years for 5 contracts in the same CPV group (3365…), excluding framework agreements. Half of the contracts fall between the two quartiles. TED source: mostly contracts above the EU thresholds, so amounts tend to be high.
Similar contracts already awarded
| Contract | Winner | Amount |
|---|---|---|
| Rituximab Cliniques universitaires Saint Luc · 19 August 2026 |
Celltrion Healthcare Netherlands B.V. | €628,800 |
| Infliximab Cliniques universitaires Saint Luc · 19 August 2026 |
Celltrion Healthcare Netherlands B.V. | €2,492,000 |
| Bévacizumab Cliniques universitaires Saint Luc · 7 July 2026 |
Celltrion Healthcare Netherlands B.V. | €503,440 |
| Pomalidomide Cliniques universitaires Saint Luc · 19 May 2026 |
EG | €268,870 |
| Antimycotica AZ Delta vzw · 21 October 2026 |
Arega Pharma NV Sandoz NV Fresenius Kabi NV Pfizer NV |
€300,945 |
Source : TED – Office des publications de l'Union européenne © Union européenne, données retraitées. Reference 731370-2026.